NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
Clinical Trials
27 trialsNCT06075615 2025-02-07
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
Pfizer
Withdrawn
NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
NCT05082493 2024-06-06
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
WPD Pharmaceuticals Sp. z o.o.
Phase 1 Withdrawn
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT05222165 2023-02-23
NEWEL
Helsinn Healthcare SA
Phase 1/2 Withdrawn
NCT05218408 2023-02-16
CYNK001GBM02
Celularity Incorporated
Phase 1/2 Withdrawn
NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04315246 2022-07-15
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Y-mAbs Therapeutics
Phase 1/2 Withdrawn
NCT04065087 2022-03-17
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Genexine, Inc.
Phase 1/2 Withdrawn
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT02876003 2017-02-24
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
GenSpera, Inc.
Phase 2 Withdrawn
NCT00992173 2015-11-26
Efficacy and Safety of Ultratraceā¢ Iobenguane I 131 in Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01225510 2015-03-11
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Pfizer
Phase 2 Withdrawn
NCT00378235 2014-11-13
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Withdrawn
NCT01778088 2014-02-25
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Cellectar Biosciences, Inc.
Phase 2 Withdrawn
NCT01697514 2013-08-27
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Eli Lilly and Company
Phase 1 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00083447 2009-01-07
Study of Therapy With TransMIDā¢ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
Xenova Biomedix
Phase 3 Withdrawn
NCT00226668 2008-01-03
XERECEPTĀ® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Celtic Pharma Development Services
Phase 3 Withdrawn